Omega Design Corporation Introduces LabelSync 450 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Omega Design Corporation Introduces LabelSync 450

Pharmaceutical Technology
Volume 37, Issue 9, pp. 14
Omega LabelSync 450

Omega Design Corporation offers the LabelSync 450 Vision Module, designed to capture and sync a bottle’s unique serialized label with its individual line code. The machine can handle bottles 30-1500 mL in volume at speeds up to 300 per minute. Compatible with a range of serialization software and vision components, the LabelSync 450 verifies each code’s readability, confirms that each bottle belongs on the line, establishes a one-to-one relationship between the two codes, and enables high-integrity identification processes downstream. The LabelSync 450’s vision system is comprised of four cameras whose combined viewpoints offer 360-degree label inspection, as well as a fifth camera to read secondary line code.

Omega Design Corporation

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here